Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 10;11(2):408.
doi: 10.3390/vaccines11020408.

Innate and Adaptive Immunity during SARS-CoV-2 Infection: Biomolecular Cellular Markers and Mechanisms

Affiliations
Review

Innate and Adaptive Immunity during SARS-CoV-2 Infection: Biomolecular Cellular Markers and Mechanisms

Brent Brown et al. Vaccines (Basel). .

Abstract

The coronavirus 2019 (COVID-19) pandemic was caused by a positive sense single-stranded RNA (ssRNA) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, other human coronaviruses (hCoVs) exist. Historical pandemics include smallpox and influenza, with efficacious therapeutics utilized to reduce overall disease burden through effectively targeting a competent host immune system response. The immune system is composed of primary/secondary lymphoid structures with initially eight types of immune cell types, and many other subtypes, traversing cell membranes utilizing cell signaling cascades that contribute towards clearance of pathogenic proteins. Other proteins discussed include cluster of differentiation (CD) markers, major histocompatibility complexes (MHC), pleiotropic interleukins (IL), and chemokines (CXC). The historical concepts of host immunity are the innate and adaptive immune systems. The adaptive immune system is represented by T cells, B cells, and antibodies. The innate immune system is represented by macrophages, neutrophils, dendritic cells, and the complement system. Other viruses can affect and regulate cell cycle progression for example, in cancers that include human papillomavirus (HPV: cervical carcinoma), Epstein-Barr virus (EBV: lymphoma), Hepatitis B and C (HB/HC: hepatocellular carcinoma) and human T cell Leukemia Virus-1 (T cell leukemia). Bacterial infections also increase the risk of developing cancer (e.g., Helicobacter pylori). Viral and bacterial factors can cause both morbidity and mortality alongside being transmitted within clinical and community settings through affecting a host immune response. Therefore, it is appropriate to contextualize advances in single cell sequencing in conjunction with other laboratory techniques allowing insights into immune cell characterization. These developments offer improved clarity and understanding that overlap with autoimmune conditions that could be affected by innate B cells (B1+ or marginal zone cells) or adaptive T cell responses to SARS-CoV-2 infection and other pathologies. Thus, this review starts with an introduction into host respiratory infection before examining invaluable cellular messenger proteins and then individual immune cell markers.

Keywords: B-cells; COVID-19; NK-cells; SARS-CoV-2; T-cells; adaptive; adhesion molecules; antibody; chemokines; cluster of differentiation; cytokines; dendritic cells; innate; macrophages; monocytes; neutrophils; proteins; receptors; serology.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Overview of SARS-CoV-2 immune cell interactions.
Figure 2
Figure 2
B cell and T cell interactions.
Figure 3
Figure 3
B cell phenotypes during maturation.
Figure 4
Figure 4
Antigen presenting cell roles in SARS-CoV-2 infection.
Figure 5
Figure 5
Monocyte cell phenotypes.
Figure 6
Figure 6
Macrophage process and role in infection.
Figure 7
Figure 7
Macrophage phenotypes during polarization.
Figure 8
Figure 8
Functional diversity of dendritic cells in maturation.
Figure 9
Figure 9
Dendritic cell phenotypes.
Figure 10
Figure 10
Natural killer cell phenotype diversity and maturation.
Figure 11
Figure 11
T-Cell phenotype diversity and developmental cellular markers.
Figure 12
Figure 12
T cell phenotype diversity and developmental cellular markers.

Similar articles

Cited by

References

    1. Muralidar S., Ambi S.V., Sekaran S., Krishnan U.M. The Emergence of COVID-19 as a Global Pandemic: Understanding the Epidemiology, Immune Response and Potential Therapeutic Targets of SARS-CoV-2. Biochimie. 2020;179:85–100. doi: 10.1016/j.biochi.2020.09.018. - DOI - PMC - PubMed
    1. Cohen S.A., Kellogg C., Equils O. Neutralizing and Cross-Reacting Antibodies: Implications for Immunotherapy and SARS-CoV-2 Vaccine Development. Hum. Vaccines Immunother. 2021;17:84–87. doi: 10.1080/21645515.2020.1787074. - DOI - PMC - PubMed
    1. Vivanti A.J., Vauloup-Fellous C., Prevot S., Zupan V., Suffee C., do Cao J., Benachi A., de Luca D. Transplacental Transmission of SARS-CoV-2 Infection. Nat. Commun. 2020;11:3572. doi: 10.1038/s41467-020-17436-6. - DOI - PMC - PubMed
    1. Mahendra M., Nuchin A., Kumar R., Shreedhar S., Mahesh P.A. Predictors of Mortality in Patients with Severe COVID-19 Pneumonia—A Retrospective Study. Adv. Respir. Med. 2021;89:135–144. doi: 10.5603/ARM.a2021.0036. - DOI - PubMed
    1. Zandi M., Shafaati M., Kalantar-Neyestanaki D., Pourghadamyari H., Fani M., Soltani S., Kaleji H., Abbasi S. The Role of SARS-CoV-2 Accessory Proteins in Immune Evasion. Biomed. Pharmacother. 2022;156:113889. doi: 10.1016/j.biopha.2022.113889. - DOI - PMC - PubMed